TrialLeukemia research2021

A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

Jonathan A Webster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.